Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?

Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers. Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Y., Sørensen, M. G., Zheng, Q., Zhang, C., Karsdal, M. A., Henriksen, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388459/
https://www.ncbi.nlm.nih.gov/pubmed/22779024
http://dx.doi.org/10.1155/2012/209409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388459/
https://www.ncbi.nlm.nih.gov/pubmed/22779024
http://dx.doi.org/10.1155/2012/209409

Ejemplares similares